The DOI matches its Crossref record.
Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future
Abstract
Non‐nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) have become an inherent ingredient of the drug combination schemes that are currently used in the treatment of human immunodeficiency virus type 1 (HIV‐1) infections. Starting from the 1‐[(2‐hydroxyethoxy)methyl]‐6‐(phenylsulfanyl)thymine (HEPT) and 4,5,6,7‐tetrahydroimidazo[4,5,1‐jk][1,4]benzodiazepin‐2(1 H)‐one and ‐thione (TIBO) derivatives, numerous classes of compounds have been described as NNRTIs. Only three compounds have so far been approved for clinical use: nevirapine, delavirdine, and efavirenz. NNRTIs are notorious for rapidly leading to virus‐drug resistance development, primarily based on the emergence of the K103N and Y181C mutations in the HIV‐1 RT. Newer NNRTIs, such as capravirine, dapivirine (TMC 125), and DPC 083, are resilient to these ‘NNRTI’ mutations, and, therefore, offer considerable promise as future anti‐HIV‐1 drugs. NNRTIs are targeted at a specific ‘pocket’ binding site within the HIV‐1 RT, that is distinct from, but both spatially and functionally related to, the catalytic site, where the nucleoside RT inhibitors (NRTIs) and nucleotide RT inhibitors (NtRTIs) interact. NNRTIs have acquired a definitive position, as part of a combination regimen with NRTIs and NtRTIs, in the first‐line treatment of HIV‐1 infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 520
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
de Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
Mehellou, Y., & De Clercq, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900492g · Cited by 368
Self-citation
Metadata
- Authors
- De Clercq, E.
- Venue
- Chemistry & Biodiversity
- Publisher
- Wiley
- Published
- 2004-01
- Volume
- 1
- Issue
- 1
- Pages
- 44-64
- ISSN
- 1612-1872 (ISSN-L)
- 1612-1880
- OpenAlex
- W2143910776
- Cited by
- 238
- References
- 0
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future. https://app.cochat.ai/papers/10.1002/cbdv.200490012
- The paper
- De Clercq, E. (2004). Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.200490012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.